毕得医药股价连续5天下跌累计跌幅5.76%，交银施罗德基金旗下1只基金持47.51万股，浮亏损失167.71万元

Group 1 - Bid Pharma's stock price fell by 1.67% on February 26, closing at 57.78 yuan per share, with a total market capitalization of 5.251 billion yuan [1] - The company has experienced a continuous decline in stock price for five consecutive days, with a cumulative drop of 5.76% during this period [1] - Bid Pharma focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among Bid Pharma's top ten circulating shareholders, a fund under China Universal Asset Management has entered the list, holding 475,100 shares, which accounts for 1.1% of the circulating shares [2] - The fund, named China Universal Medical Innovation Stock A, has reported a year-to-date return of 0.08% and a one-year return of 19.93% [2] - The fund manager, Lou Huiyuan, has a tenure of 7 years and 170 days, with the best fund return during this period being 127.51% [2]